The sympathetic system and hypertension*1
Population
Patients with lean essential hypertension, normotensive obesity, obesity-related hypertension, and heart…
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
Supports sympathetic targeting in hypertension; leaves open outcome trials of I1 agents before practice change.
Structured PICO
P
Population
Patients with lean essential hypertension, normotensive obesity, obesity-related hypertension, and heart failure
I
Intervention
I1 agents (e.g., rilmenidine)
The sympathetic nervous system plays a central role in the pathophysiology of both lean and obesity-related hypertension, and centrally acting I1 agents like rilmenidine offer a targeted therapeutic approach.
Cite This Study
Murray Esler (2000) studied this question.